首页 | 本学科首页   官方微博 | 高级检索  
     


Time of PTV is ending,robust optimization comes next
Affiliation:1. Department of Radiation Oncology, centre Léon-Bérard, 28, rue Laennec 69373 Lyon cedex 08, France;2. Creatis, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, Villeurbanne, France;3. Department of Medical Physics, Institut de cancérologie de l’Ouest, Saint-Herblain, France;4. Department of radiation oncology, centre François-Baclesse/ARCHADE, Laboratoire de physique corpusculaire IN2P3/ENSICAEN–UMR6534, Unicaen, Normandie Universite, Caen, France;5. Department of Medical Physics, centre Oscar-Lambret, Lille, France;1. Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand Cedex 1, France;2. Département de radiothérapie, centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France;3. Département de radiothérapie, institut universitaire du cancer de Toulouse, 1, avenue Irene Joliot-Curie, 31100 Toulouse, France;1. CNAO, National Center for Oncological Hadrontherapy, Pavia, Italy;2. Politecnico di Milano, Italy;1. Department of Medical Physics, Aarhus University Hospital, Denmark;2. Department of Radiation Oncology, Heidelberg University Hospital, Germany;3. Department of Oncology, Aarhus University Hospital, Denmark;1. Radiation Oncology Department, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France;2. Department of Otolaryngology-Head and Neck Surgery/Skull Base Surgery, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France;3. Université Paris-Diderot, 5, rue Thomas-Mann, 75013 Paris, France;4. Radiation Oncology Department, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France;5. Radiation Oncology Department, CHU d’Amiens, 1, rue du Professeur-Christian-Cabrol, 80054 Amiens, France;6. Oncologic Surgery Department, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France;7. Oncologic Surgery Department, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France;8. Association Advance Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France;1. Division of Radiotherapy, University Hospital Maggiore della Carità, Novara, Italy;2. Division of Radiation Oncology, Sichuan Cancer Center, Chengdu, China;3. Medical Physics, University Hospital Maggiore della Carità, Novara, Italy;4. Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy;1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;2. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA;3. Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, China;4. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;5. Global Oncology One, Houston, USA;6. Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;7. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, USA
Abstract:Continuous improvements have been made in the way to prescribe, record and report dose distributions since the therapeutic use of ionizing radiations. The international commission for radiation units and measurement (ICRU) has provided a common language for physicians and physicists to plan and evaluate their treatments. The PTV concept has been used for more than two decades but is becoming obsolete as the CTV-to-PTV margin creates a static dose cloud that does not properly recapitulate all planning vs. delivery uncertainties. The robust optimization concept has recently emerged to overcome the limitations of the PTV concept. This concept is integrated in the inverse planning process and minimizes deviations to planned dose distribution through integration of uncertainties in the planning objectives. It appears critical to account for the uncertainties that are specific to protons and should be accounted for to better exploit the clinical potential of proton therapy. It may also improve treatment quality particularly in hypofractionated photon plans of mobile tumors and more widely to photon radiotherapy. However, in contrast to the PTV concept, a posteriori evaluation of plan quality, called robust evaluation, using error-based scenarios is still warranted. Robust optimization metrics are warranted. These metrics are necessary to compare PTV-based photon and robustly optimized proton plans in general and in model-based NTCP approaches. Assessment of computational demand and approximations of robust optimization algorithms along with metrics to evaluate plan quality are needed but a step further to better prescribe radiotherapy may has been achieved.
Keywords:Radiotherapy  CTV  PTV  Robust optimization  Uncertainties  Radiothérapie  volume cible prévisionnel  volume cible anatomoclinique  Optimisation robuste  Incertitudes
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号